Core Viewpoint - Kweichow Moutai has received a notice of acceptance for the registration application of Duzhuaiyin capsules from the National Medical Products Administration, indicating progress in the approval process for a new product aimed at treating osteoarthritis in hip and knee joints [1] Group 1 - The product is classified as a chemical drug of category 4 and is in capsule form, targeting osteoarthritis treatment [1] - The company plans to actively promote the product's licensing work and will continue to monitor the approval status [1]